Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.10.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 6 Months Ended
Apr. 01, 2018
Jul. 01, 2017
Jun. 01, 2017
Dec. 31, 2017
Aug. 16, 2017
Jul. 25, 2017
Oct. 27, 2016
Apr. 25, 2016
Feb. 17, 2015
Dec. 31, 2014
Jan. 31, 2011
Jun. 30, 2018
Jun. 30, 2017
Aug. 16, 2018
Oct. 09, 2017
Commitments and Contingencies (Textual)                              
Accrued royalties                       $ 60,000      
Royalties due amount                       40,000      
Patent reimbursements                       38,246      
Performance bonus plan, description                 Under the PBP, 5.25% of the first $14.7 million of a strategic transaction (one or more transactions that provide funds to the Company and/or its members that enable the commencement of the clinical development of AD04) will be set aside for Company’s personnel with 1.25% of funds to be awarded to the Chairman of the Board and the remainder to be awarded at the CEO’s discretion, with no more than 3.15% payout to the CEO of the Company. The maximum bonus amount to be paid out of the PBP was $771,750. The Company had the right to pay up to 65% of the amounts due under the PBP with equity of the Company, valued at a future investors round equity price, with the balance paid in cash in order to potentially pay taxes that may be due by the recipients due to the award under the PBP.            
Associated charge to operations                       1,500,000      
Chair of the Board will receive a cash stipend                       $ 49,000      
Options vesting, price   $ 5.70                          
Description of vesting rights   Options are to purchase shares of common stock at a price of $5.70 per share, the options vesting over three years and with a term of ten years, the first 1/6th vesting only after 6 months, then 1/36th vesting each month for the remaining 30 months.       Options are to purchase shares of common stock at a price of $5.70 per share and have a term of ten years. These options vest over three years, the first 1/6th vesting only after 6 months, then 1/36th vesting each month for the remaining 30 months.                  
Employment agreements terms, description           These terms were memorialized in forms of employment agreements to be entered into by the Company and the executive officers referred to above upon consummation of the IPO for terms of five, three, and three years, respectively, with customary terms of severance. Following the consummation of the IPO on July 31, 2018, these executive officers executed their respective employment agreements.                  
Grant incentive plan, description The Company will make a yearly payment to the Plan Participants, based on the grant funding received by the Company in the preceding year from grants originated by the Plan Participants, in an amount equal to 10% of the first $1 million of grant funding received and 5% of grant funding received in the preceding year above $1 million. Amounts to be paid to the Plan Participants will be paid to each as follows: 50% in cash and 50% in stock no later than March 31, each year.                            
Contract research organizations, description                       The Company issued the CRO an option to invest $100,000 in the Company’s next financing of $3,000,000 on terms equal to those received by investors but at a 15% discount to the lowest price paid by such investors. In the event the Company is acquired prior to such a financing, the CRO also has the option to purchase 13,099 shares of common stock at a price of $7.63 per share (i.e. $100,000 total purchase price). This option expired on March 14, 2021 or upon completion of the Company’s financing. On July 31, 2018, this option expired, unexercised.      
Sublease, description         The Company has agreed to pay rent in the amount of $300 per month while it is a private company with the rent increasing to $1,300 per month beginning on the first day of the month after it is a public company.                    
Rent expense                       $ 3,900 $ 750    
2017 equity incentive plan [Member]                              
Commitments and Contingencies (Textual)                              
Shares of equity incentive plan                             1,750,000
Securities and Exchange Commission [Member] | Subsequent Event [Member]                              
Commitments and Contingencies (Textual)                              
Shares of equity incentive plan                           1,750,000  
Consulting Agreement [member]                              
Commitments and Contingencies (Textual)                              
Compensation rate of consulting agreement     $ 2,200 $ 3,200                      
Consultant fees                       $ 19,200 $ 12,200    
Consulting agreement, description             The consultant will receive equity, which will be in the form of restricted common stock at the completion of an IPO in an amount equal to 4.8% of the common stock outstanding immediately prior to the IPO. Shares shall vest on completion of the IPO. In addition, immediately following an Offering, the Company shall issue the consultant 5-year warrants to purchase such number of shares of common equity of the Company equal to 4.9% of the then total fully diluted outstanding shares with an exercise price equal to the price of the shares issued in the Offering.                
Lease Commitments [member]                              
Commitments and Contingencies (Textual)                              
Monthly payments of lease                   $ 2,250          
Lease terminated                   Terminated on January 31, 2017.          
Licensing & Venture Group [Member]                              
Commitments and Contingencies (Textual)                              
License agreement description                     The Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.        
License agreement notice period, description                     The license agreement may be terminated by UVA LVG upon sixty (60) days written notice if the Company breaches its obligations thereunder, including failing to make any milestone, the most immediate being initiating Phase 3 clinical trials by December 31, 2018, making required payments or the failure to exercise diligence to bring licensed products to market.        
Mr. Stilley [Member]                              
Commitments and Contingencies (Textual)                              
Shares of common stock $ 197,673                            
Percentage of annual salary [1]   30.00%                          
Annual salary   $ 350,000                          
Dr. Johnson [Member]                              
Commitments and Contingencies (Textual)                              
Shares of common stock 50,000                            
Mr. Truluck [Member]                              
Commitments and Contingencies (Textual)                              
Shares of common stock $ 44,636                            
COO/CFO1 [Member]                              
Commitments and Contingencies (Textual)                              
Compensation rate of consulting agreement               $ 2,000              
Percentage of annual salary [1],[2]   20.00%                          
Annual salary [2]   $ 143,000                          
Officers and Director [Member]                              
Commitments and Contingencies (Textual)                              
Percentage of annual salary   50.00%                          
Annual salary   $ 286,000                          
Chief Development Officer One [Member]                              
Commitments and Contingencies (Textual)                              
Percentage of annual salary                       70.00%      
Annual salary                       $ 371,000      
[1] As a percentage of Annual Salary. The target annual bonus will be awarded for meeting performance goals set by the board of directors, with the potential for an additional award not to exceed a third of the target annual bonus for exemplary performance awarded at the discretion of the board of directors.
[2] Annual salary is for 50% of full time, on a full-time equivalent basis of $286,000 annually.